Holen Sie sich die Stockscreener-App
332.92
0.51%
1.68
Alnylam Pharmaceuticals Inc Aktie (ALNY) Neueste Nachrichten
Alnylam’s New Phase 1 ALN-4285 Trial: What Early Safety Data Could Mean for ALNY Investors - TipRanks
Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Westfield Capital Management Co. LP - MarketBeat
A Look At Alnylam Pharmaceuticals (ALNY) Valuation After Recent Share Price Pullback - simplywall.st
Alnylam Pharmaceuticals Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
TD Asset Management Inc Sells 128,660 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Why Alnylam Pharmaceuticals Stock Slipped Today - AOL.com
Reassessing Alnylam Pharmaceuticals (ALNY) After Recent Share Price Weakness - simplywall.st
Will Alnylam’s (ALNY) 2025 Profitability and $2.26 Billion Shelf Filing Redefine Its Risk Profile? - simplywall.st
Alnylam to Webcast Presentation at TD Cowen 46th Annual Health Care Conference - BioSpace
Here's How Much $100 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth Today - Benzinga
Understanding the Setup: (ALNY) and Scalable Risk - Stock Traders Daily
Fiera Capital Corp Grows Stake in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
NewEdge Wealth LLC Buys 7,091 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
ANTIPODES PARTNERS Ltd Cuts Stake in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Will Alnylam Pharmaceuticals Inc. stock benefit from automationTrade Risk Summary & High Return Stock Watch Alerts - mfd.ru
China Universal Asset Management Co. Ltd. Cuts Stake in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals (ALNY) Reports $3B 2025 Revenue Driven by 151% TTR Franchise Surge - Insider Monkey
Assessing Alnylam Pharmaceuticals (ALNY) Valuation After First Profitable Year And Rapid Revenue Growth - simplywall.st
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Moderna (MRNA) and NewAmsterdam Pharma Company (NAMS) - The Globe and Mail
Shifting Trends in Biotechnology Mergers and Acquisitions - Intellectia AI
Regeneron Pharmaceuticals Inc. Lowers Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Rating Upgraded by Freedom Capital - MarketBeat
Oligonucleotide Therapy Market to hit US$ 40.16 Billion by 2033 | - openPR.com
RNAi Therapeutics Market to hit US$ 8.80 Billion by 2033 | North - openPR.com
11,700 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Bought by Alberta Investment Management Corp - MarketBeat
1 Reason I'd Buy Eli Lilly Stock and Never Sell - AOL.com
Analysts Trim Alnylam Pharmaceuticals, Inc. (ALNY) Targets but Keep Faith in 2026 Growth - Finviz
Alnylam Pharmaceuticals' (ALNY) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
HC Wainwright Reiterates Buy Rating on ALNY with Price Target at $510 | ALNY Stock News - GuruFocus
Insider Unloading: Jeffrey V Poulton Sells $695K Worth Of Alnylam Pharmaceuticals Shares - Benzinga
EVP Of Alnylam Pharmaceuticals Makes $607K Sale - Benzinga
Sell Alert: Yvonne Greenstreet Cashes Out $2.16M In Alnylam Pharmaceuticals Stock - Benzinga
Inflation Data: Whats the beta of Alnylam Pharmaceuticals Inc stockM&A Rumor & Verified Short-Term Trading Plans - baoquankhu1.vn
Alnylam Pharmaceuticals, Inc. $ALNY Shares Purchased by Merit Financial Group LLC - Defense World
Eagle Health Investments LP Sells 22,400 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Skandinaviska Enskilda Banken AB publ - MarketBeat
Assessing Alnylam Pharmaceuticals (ALNY) Valuation As Mixed Share Price Returns Meet Bullish Fair Value Models - Yahoo Finance
Alnylam’s First Profitable Year Tests Durability Of TTR RNAi Franchise - simplywall.st
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $429.00 at Canaccord Genuity Group - Defense World
Why Alnylam Pharmaceuticals Stock Was Soaring on Monday - AOL.com
Alnylam EVP Garg sells $695k in stock to cover tax obligations - Investing.com
Jeffrey Poulton Sells 2,242 Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Tolga Tanguler Sells 1,959 Shares - MarketBeat
Yvonne Greenstreet Sells 6,958 Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Pushkal Garg Sells 2,242 Shares - MarketBeat
Alnylam shares jump as investors focus on profitability and upbeat 2026 revenue outlook - Quiver Quantitative
ALNY: Freedom Capital Markets Upgrades Rating Despite Lower Pric - GuruFocus
Alnylam: Strong Amvuttra Outperformance and High-Value Pipeline Optionality Support Buy Rating - TipRanks
ALNY: Canaccord Genuity Raises Price Target in Latest Analyst Up - GuruFocus
Canaccord Genuity Group Forecasts Strong Price Appreciation for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock - MarketBeat
Alnylam stock rating upgraded at Freedom Capital on AMVUTTRA growth By Investing.com - Investing.com UK
Vanguard Group Inc. Buys 268,313 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Principal Financial Group Inc. Sells 45,114 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
ABN Amro Investment Solutions Has $597,000 Stake in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam targets 25% revenue CAGR through 2030 amid AMVUTTRA launch momentum and pipeline expansion - MSN
Should You Add Alnylam Pharmaceuticals (ALNY) to Your Portfolio? - MSN
Alnylam Pharmaceuticals (ALNY) Investor Outlook: Analyzing The 46% Potential Upside - DirectorsTalk Interviews
Shell Asset Management Co. Sells 4,478 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Aberdeen Group plc Sells 61,228 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Will First GAAP Profit Year and Amvuttra Expansion Shift Alnylam Pharmaceuticals' (ALNY) Narrative? - simplywall.st
Cardiovascular Biologics Market to Reach US$ 4.23 Billion - openPR.com
0.60%
1.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):